Program

13
13
1

Journal Year Published

2
3
4
3
7
3

Author

22
201
181
149
139
133
133
125
123
108
105
95
82
78
63
62
54
50
46
43
43

Category

10
10
5
2

Keyword

3
3
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1

Journal

3
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1

NCATS Publications

Novel renal medullary carcinoma cell lines, UOK353 and UOK360, provide preclinical tools to identify new therapeutic treatments.


Wei D, Yang Y, Ricketts CJ, Vocke CD, Ball M, Sourbier C, Wangsa D, Wangsa D, Guha R, Zhang X, Wilson K, Chen L, Meltzer PS, Ried T, Thomas C, Merino MJ, Linehan WM


Genes Chromosomes Cancer , 2020.

Article Pubmed

Targeting AML-associated FLT3 mutations with a type I kinase inhibitor.


Jones LM, Melgar K, Bolanos L, Hueneman K, Walker MM, Jiang J, Wilson K, Zhang X, Shen J, Jiang F, Sutter P, Wang A, Xu X, Tawa G, Hoyt S, Wunderlich M, O'Brien E, Perentesis JP, Starczynowski DT, Thomas C


J. Clin. Invest. , (130), 2017-2023, 2020.

Article Pubmed

Sample image from publication page

Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening.


Lin GL, et al.


Sci Transl Med , (11), 2019.

Article Pubmed

Sample image from publication page

Overcoming adaptive therapy resistance in AML by targeting immune response pathways.


Melgar K, Walker MM, Jones LM, Bolanos LC, Hueneman K, Wunderlich M, Jiang J, Wilson K, Zhang X, Sutter P, Wang A, Xu X, Choi K, Tawa G, Lorimer D, Abendroth J, O'Brien E, Hoyt S, Berman E, Famulare CA, Mulloy JC, Levine RL, Perentesis JP, Thomas C, Starczynowski DT


Sci Transl Med , (11), 2019.

Article Pubmed

Sample image from publication page

High-throughput screening identifies candidate drugs for the treatment of recurrent respiratory papillomatosis.


Alkhilaiwi F, Paul S, Zhou D, Zhang X, Wang F, Palechor-Ceron N, Wilson K, Guha R, Ferrer-Alegre M, Grant N, Thomas C, Schlegel R, Yuan H


Papillomavirus Res , (8), 100181, 2019.

Article Pubmed

Sample image from publication page

High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer.


Jansson KH, Tucker JB, Stahl LE, Simmons JK, Fuller C, Beshiri ML, Agarwal S, Fang L, Hynes PG, Alilin AN, Lake R, Abbey YC, Cawley J, Tice CM, Yin J, McKnight C, Klumpp-Thomas C, Zhang X, Guha R, Hoover S, Simpson RM, Nguyen HM, Corey E, Thomas C, Proia DA, Kelly K


Sci Rep , (8), 17239, 2018.

Article Pubmed

MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma.


Yohe ME, Gryder BE, Shern JF, Song YK, Chou HC, Sindiri S, Mendoza A, Patidar R, Zhang X, Guha R, Butcher D, Isanogle KA, Robinson CM, Luo X, Chen JQ, Walton A, Awasthi P, Edmondson EF, Difilippantonio S, Wei JS, Zhao K, Ferrer-Alegre M, Thomas C, Khan J


Sci Transl Med , (10), 2018.

Article Pubmed

Sample image from publication page

Pharmacological and genomic profiling of neurofibromatosis type 1 plexiform neurofibroma-derived schwann cells.


Ferrer-Alegre M, Gosline SJC, Stathis M, Zhang X, Guo X, Guha R, Ryman DA, Wallace MR, Kasch-Semenza L, Hao H, Ingersoll R, Mohr D, Thomas C, Verma S, Guinney J, Blakeley JO


Sci Data , (5), 180106, 2018.

Article Pubmed

Functional screening of FGFR4-driven tumorigenesis identifies PI3K/mTOR inhibition as a therapeutic strategy in rhabdomyosarcoma.


McKinnon T, Venier R, Yohe M, Sindiri S, Gryder BE, Shern JF, Kabaroff L, Dickson B, Schleicher K, Chouinard-Pelletier G, Menezes S, Gupta A, Zhang X, Guha R, Ferrer-Alegre M, Thomas C, Wei Y, Davani D, Guidos CJ, Khan J, Gladdy RA


Oncogene , 2018.

Article Pubmed

Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma.


Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau D, Guha R, Ferrer-Alegre M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas C


Clin. Cancer Res. , 2017.

Article Pubmed

Sample image from publication page